


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Composition containing an androgenic  $11\beta$ -halogen steroid, selected from the group of compounds of general formula I



in which

X-Y-Z represents a group with one of the two structures  $\text{CH}=\text{C-C}$  or  $\text{CH}_2\text{-C=C}$ ,

$\text{R}^1$  can be in  $\alpha$ -position and  $\beta$ -position and stands for hydrogen, R or P-Q-R that is bonded via P to the basic ring structure, whereby P and Q represent straight-chain or branched-chain  $\text{C}_1$ - to  $\text{C}_8$ -alkylene, -alkenylene, or -alkynylene groups or their fluorinated derivatives and can be the same or different, and whereby R represents a  $\text{CH}_3$  or  $\text{CF}_3$  radical, provided that no substituent  $\text{R}^1$  is present on Z if X-Y-Z represents the group  $\text{CH}_2\text{-C=C}$ ,

$\text{R}^6$  is a hydrogen atom or can have the meanings that are indicated under  $\text{R}^7$ ,

$\text{R}^7$  stands for R or P-Q-R that is bonded via P to the basic ring structure, whereby these groups have the previously mentioned meanings,

$\text{R}^{11}$  represents a halogen,

$\text{R}^{13}$  is methyl or ethyl, and


R<sup>17</sup> is hydrogen or stands for C(O)-R<sup>18</sup>, whereby

R<sup>18</sup> is a straight-chain or branched-chain C<sub>1</sub>- to C<sub>18</sub>-alkyl, -alkenyl, or -alkinyl radical or an aryl radical, or stands for T-U-V that is bonded via P to the C(O) group, whereby T and U represent straight-chain or branched-chain C<sub>1</sub>- to C<sub>18</sub>-alkylene, -alkenylene,

-alkinylene groups, alicyclic C<sub>3</sub>- to C<sub>12</sub> groups or aryl groups and are the same or different, and V is a straight-chain or branched-chain C<sub>1</sub>- to C<sub>18</sub>-alkyl-, -alkenyl- or -alkinyl radical or an aryl radical, or

R<sup>18</sup> has one of the previously mentioned meanings and in addition is substituted with one or more groups NR<sup>19</sup>R<sup>20</sup> or one or more groups SO<sub>x</sub>R<sup>21</sup>, whereby x = 0, 1 or 2, and R<sup>19</sup>, R<sup>20</sup> and R<sup>21</sup> in each case are hydrogen or T-U-V that is bonded via T to N, S with the previously mentioned meaning, provided that in addition, the physiologically compatible addition salts with inorganic and organic acids are included,

and the gestagen of the formula below.



2. (Original) Composition according to claim 1, characterized in that the 11 $\beta$ -halogen steroid of general formula I is the compound 11 $\beta$ -fluoro-17 $\beta$ -hydroxy-7 $\alpha$ -methyl-estr-4-en-3-one.

3. (Original) Pharmaceutical composition containing a composition according to claim 1 as well as a pharmaceutically compatible vehicle and/or adjuvants.

4. (Original) Pharmaceutical composition according to claim 3, wherein the 11 $\beta$ -halogen steroid of general formula I is the compound 11 $\beta$ -fluoro-17 $\beta$ -hydroxy-7 $\alpha$ -methyl-estr-4-en-3-one.

5. (Original) Male contraceptive agent containing a pharmaceutical composition according to claim 3.

6. (Original) Male contraceptive agent containing a pharmaceutical composition according to claim 4.

7. (Currently Amended) Male contraceptive agent according to claim 5 or 6, wherein the androgenic compound of general formula I is formulated pharmaceutically such that the latter can be implanted in the body of the male user over an extended period such that the androgenic compound is released continuously over this extended period to the organism of the user.

8. (Currently Amended) Male contraceptive agent according to claim 5 or 6, wherein the androgenic compound of general formula I is provided therein for oral administration.

9. (Currently Amended) Male contraceptive agent according to claim 5 or 6, wherein the gestagen therein is formulated pharmaceutically such that it is released to the body of the male user over an extended period.

10. (Original) Male contraceptive agent according to claim 9, wherein the gestagen is formulated such that the latter can be implanted in the body of the male user over an extended period, such that the gestagen is released continuously over this extended period to the organism of the user.

11. (Original) Male contraceptive agent according to claim 10, wherein the gestagen is formulated in a transdermal system.

12. (Currently Amended) Male contraceptive agent according to claim 5 or 6, wherein the gestagen is formulated for oral administration.